The Emergence of HIV Transmitted Resistance in Botswana: “When Will the WHO Detection Threshold Be Exceeded?”

Background The Botswana antiretroviral program began in 2002 and currently treats 42,000 patients, with a goal of treating 85,000 by 2009. The World Health Organization (WHO) has begun to implement a surveillance system for detecting transmitted resistance that exceeds a threshold of 5%. However, the WHO has not determined when this threshold will be reached. Here we model the Botswana government's treatment plan and predict, to 2009, the likely stochastic evolution of transmitted resistance. Methods We developed a model of the stochastic evolution of drug-resistant strains and formulated a birth-death Master equation. We analyzed this equation to obtain an analytical solution of the probabilistic evolutionary trajectory for transmitted resistance, and used treatment and demographic data from Botswana. We determined the temporal dynamics of transmitted resistance as a function of: (i) the transmissibility (i.e., fitness) of the drug-resistant strains that may evolve and (ii) the rate of acquired resistance. Results Transmitted resistance in Botswana will be unlikely to exceed the WHO's threshold by 2009 even if the rate of acquired resistance is high and the strains that evolve are half as fit as the wild-type strains. However, we also found that transmission of drug-resistant strains in Botswana could increase to ∼15% by 2009 if the drug-resistant strains that evolve are as fit as the wild-type strains. Conclusions Transmitted resistance will only be detected by the WHO (by 2009) if the strains that evolve are extremely fit and acquired resistance is high. Initially after a treatment program is begun a threshold lower than 5% should be used; and we advise that predictions should be made before setting a threshold. Our results indicate that it may be several years before the WHO's surveillance system is likely to detect transmitted resistance in other resource-poor countries that have significantly less ambitious treatment programs than Botswana.

[1]  P. Weidle,et al.  Assessment of a pilot antiretroviral drug therapy programme in Uganda: patients' response, survival, and drug resistance , 2002, The Lancet.

[2]  Neil M Ferguson,et al.  Modelling the Impact of Antiretroviral Use in Resource-Poor Settings , 2006, PLoS medicine.

[3]  H. Gershengorn,et al.  Predicting the unpredictable: Transmission of drug-resistant HIV , 2001, Nature Medicine.

[4]  S. Hammer,et al.  Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy. , 2004, The New England journal of medicine.

[5]  F. Mammano,et al.  Resistance-Associated Loss of Viral Fitness in Human Immunodeficiency Virus Type 1: Phenotypic Analysis of Protease andgag Coevolution in Protease Inhibitor-Treated Patients , 1998, Journal of Virology.

[6]  M A Fischl,et al.  A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. , 1997, The New England journal of medicine.

[7]  G. Maartens,et al.  Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa , 2004, AIDS.

[8]  Charles J. Mode,et al.  Stochastic Processes in Epidemiology: Hiv/Aids, Other Infectious Diseases and Computers , 2000 .

[9]  D. Pillay,et al.  Transmission of HIV-1 drug resistance. , 2004, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[10]  H. Limburg,et al.  Field trial of applicability of lot quality assurance sampling survey method for rapid assessment of prevalence of active trachoma. , 2003, Bulletin of the World Health Organization.

[11]  R. Plackett.  An introduction to the theory of statistics , 1972 .

[12]  H. Gershengorn,et al.  A tale of two futures: HIV and antiretroviral therapy in San Francisco. , 2000, Science.

[13]  M. Segal,et al.  Higher CD4+ T cell counts associated with low viral pol replication capacity among treatment-naive adults in early HIV-1 infection. , 2004, The Journal of infectious diseases.

[14]  J. Wolfowitz,et al.  An Introduction to the Theory of Statistics , 1951, Nature.

[15]  A. Wensing,et al.  Worldwide transmission of drug-resistant HIV. , 2003, AIDS reviews.

[16]  S. Blower,et al.  Predicting the epidemiological impact of antiretroviral allocation strategies in KwaZulu-Natal: The effect of the urban–rural divide , 2006, Proceedings of the National Academy of Sciences.

[17]  J. Salomon,et al.  Integrating HIV Prevention and Treatment: From Slogans to Impact , 2005, PLoS medicine.

[18]  Terri Wrin,et al.  The prevalence of antiretroviral drug resistance in the United States , 2004, AIDS.

[19]  M. Peeters,et al.  Low rate of genotypic HIV‐1 drug‐resistant strains in the Senegalese government initiative of access to antiretroviral therapy , 2003, AIDS.

[20]  D. Gillespie.  A General Method for Numerically Simulating the Stochastic Time Evolution of Coupled Chemical Reactions , 1976 .

[21]  E. Susman.  Botswana gears up to treat HIV patients in Africa's largest program. , 2004, AIDS (London).

[22]  P. Harrigan,et al.  Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy. , 2005, The Journal of infectious diseases.

[23]  B. Gazzard,et al.  Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practice , 2005, AIDS.

[24]  D. E. Barton,et al.  The Elements of Stochastic Processes with Applications to the Natural Sciences , 1964 .

[25]  M. Law,et al.  Randomized, open-Label, comparative trial to evaluate the efficacy and safety of three antiretroviral drug combinations including two nucleoside analogues and nevirapine for previously untreated HIV-1 Infection: The OzCombo 2 study , 2002, HIV clinical trials.

[26]  Alun L Lloyd,et al.  Estimating variability in models for recurrent epidemics: assessing the use of moment closure techniques. , 2004, Theoretical population biology.

[27]  D. Sutherland,et al.  WHO approach to track HIV drug resistance emergence and transmission in countries scaling up HIV treatment. , 2005, AIDS (London).

[28]  Dimitri D. Vvedensky.  Partial differential equations - with Mathematica , 1993, Physics series.

[29]  S. Blower,et al.  Forecasting the future of HIV epidemics: the impact of antiretroviral therapies & imperfect vaccines. , 2003, AIDS reviews.

[30]  T. Quinn,et al.  Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. , 2000, The New England journal of medicine.

[31]  Kholoud Porter,et al.  The empirical evidence for the impact of HIV on adult mortality in the developing world: data from serological studies , 2004, AIDS.

[32]  F. Mammano,et al.  Quantification of the Effects on Viral DNA Synthesis of Reverse Transcriptase Mutations Conferring Human Immunodeficiency Virus Type 1 Resistance to Nucleoside Analogues , 2005, Journal of Virology.

[33]  Max Essex,et al.  Barriers to Antiretroviral Adherence for Patients Living with HIV Infection and AIDS in Botswana , 2003, Journal of acquired immune deficiency syndromes.

[34]  Erin N. Bodine,et al.  The antiretroviral rollout and drug-resistant HIV in Africa: insights from empirical data and theoretical models. , 2005, AIDS.

[35]  D. Bangsberg,et al.  Adherence to HIV antiretroviral therapy in HIV+ Ugandan patients purchasing therapy , 2005, International journal of STD & AIDS.